Results 81 to 90 of about 118,712 (218)

Evaluation of HIV-DNA and inflammatory markers in HIV-infected individuals with different viral load patterns [PDF]

, 2017
Background: Persistent residual viremia (RV) and low grade inflammation and immune activation have been associated with non-AIDS defining events. The impact of persistent RV and HIV-DNA load on immune activation/ inflammation remains unclear.
Antonelli, Guido, Bon, Isabella, D'Ettorre, Gabriella, DE VITO, Corrado, Di Carlo, Daniele, Falasca, Francesca, Fantauzzi, Alessandra, Fimiani, Caterina, Mezzaroma, Ivano, Re, Maria Carla, Turriziani, Ombretta, Vullo, Vincenzo   +11 more
core   +2 more sources

Real‐world use of second‐generation integrase strand transfer inhibitors (INSTI) as switch therapy in the prospective ANRS‐CO3‐AquiVIH‐NA cohort

HIV Medicine, EarlyView.
Abstract Objectives To characterize real‐world treatment switching in France to bictegravir (BIC or B) or dolutegravir (DTG)‐based regimens with a focus on treatment persistence, effectiveness (HIV‐1 RNA ≤50 copies/ml) and particular attention to the prevalence and incidence of comorbidities. Methods People living with HIV from the prospective ANRS‐CO3‐
O. Leleux, A. Peyrouny‐Mazeau, A. Perrier, M. Hessamfar, G. Le Moal, D. Neau, L. Alleman, C. Cazanave, E. Lazaro, P. Duffau, A. Riché, Y. Gérard, G. Barrière, S. Reigadas, M.‐A. Vandenhende, F. Bonnet   +15 more
wiley   +1 more source

Primary HIV Drug Resistance among Recently Infected Cases of HIV in North-West India

AIDS Research and Treatment, 2019
Background. Antiretroviral treatment may lead to the emergence of HIV drug resistance, which can be transmitted. HIV primary drug resistance (PDR) is of great public health concern because it has the potential to compromise the efficacy of antiretroviral
C. K. Chauhan, P. V. M. Lakshmi, V. Sagar, A. Sharma, S. K. Arora, R. Kumar   +5 more
doaj   +1 more source

Discovery of Biphenyl-Substituted Diarylpyrimidines as New Non-Nucleoside HIV-1 Reverse Transcripttase Inhibitors

Proceedings, 2017
Reverse transcriptase (RT), the key enzyme in the HIV life cycle of HIV, is one of the main targets for the antiretroviral chemotherapy. [...]
Kaijun Jin, Ge Meng, Fen-Er Chen, Erik De Clercq, Christophe Pannecouque   +4 more
doaj   +1 more source

Emerging reverse transcriptase inhibitors for HIV-1 infection [PDF]

Expert Opinion on Emerging Drugs, 2018
There are 36.7 million people living with HIV with 20.9 million having access to antiretroviral therapy (ART). Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) remain the 'backbone' of ART. However, the currently available nine NRTIs and five non-nucleoside reverse transcriptase inhibitors (NNRTIs) have significant side effects and ...
Mohammad A, Rai, Sam, Pannek, Carl J, Fichtenbaum   +2 more
openaire   +2 more sources

Prevalence of low‐level viremia and its association with virological failure among adolescents living with HIV in Eastern Cape, South Africa

HIV Medicine, EarlyView.
Abstract Objectives Low‐level viremia (LLV) has been associated with an increased risk of virological failure among adults on antiretroviral therapy (ART). However, evidence on the clinical implications of LLV among adolescents living with HIV remains limited.
Zea Leon, Olanrewaju Edun, Siyanai Zhou, Janke Tolmay, Lucie Cluver, Gayle Sherman, Ahmad H. Mazanderani, Elona Toska   +7 more
wiley   +1 more source

Recent discoveries in HIV-1 reverse transcriptase inhibitors

Current Opinion in Pharmacology, 2020
HIV-1 reverse transcriptase inhibitors (RTIs) are indispensable components of highly active antiretroviral therapy (HAART), which has achieved great success in controlling AIDS epidemic in reducing drastically the morbidity and mortality of HIV-infected patients.
Gu, Shuang-Xi, Zhu, Yuan-Yuan, Wang, Chao, Wang, Hai-Feng, Liu, Gen-Yan, Cao, Shuang, Huang, Lu   +6 more
openaire   +2 more sources

HIV-1 Protease, Reverse Transcriptase, and Integrase Variation [PDF]

Journal of Virology, 2016
ABSTRACT HIV-1 protease (PR), reverse transcriptase (RT), and integrase (IN) variability presents a challenge to laboratories performing genotypic resistance testing. This challenge will grow with increased sequencing of samples enriched for proviral DNA such as dried blood spots and increased use of next-generation sequencing (NGS ...
Rhee, Soo-Yon, Sankaran, Kris, Varghese, Vici, Winters, Mark A., Hurt, Christopher B., Eron, Joseph J., Parkin, Neil, Holmes, Susan P., Holodniy, Mark, Shafer, Robert W.   +9 more
openaire   +2 more sources

A multidisciplinary, AI‐supported quality improvement intervention to manage polypharmacy in aging people with HIV

HIV Medicine, EarlyView.
Abstract Objectives Aging people with HIV are increasingly affected by multimorbidity and polypharmacy, which heighten the risk of drug–drug interactions (DDIs) and potentially inappropriate medications (PIMs). This study evaluated a multidisciplinary, AI‐supported quality improvement intervention designed to optimize polypharmacy management in older ...
Jovana Milic, Antonia Pugliese, Michela Belli, Gian Luca Lonardi, Caterina Ruffilli, Tommaso Albano, Marco Visicaro, Martina Ricciardetto, Pierluigi De Cosmo, Chiara Mussi, Francesca Gandolfi, Cristina Mussini, Costantino Grana, Giovanni Guaraldi   +13 more
wiley   +1 more source

HTLV-1 reverse transcriptase homology model provides structural basis for sensitivity to existing nucleoside/nucleotide reverse transcriptase inhibitors

Virology Journal
The human T-lymphotropic virus type 1 (HTLV-1) infects millions of people globally and is endemic to various resource-limited regions. Infections persist for life and are associated with increased susceptibility to opportunistic infections and severe ...
Nicolas Tardiota, Noushin Jaberolansar, Julia A. Lackenby, Keith J. Chappell, Jake S. O’Donnell   +4 more
doaj   +1 more source